Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,804JPY
31 Oct 2014
Price Change (% chg)

¥147 (+3.16%)
Prev Close
¥4,658
Open
¥4,725
Day's High
¥4,861
Day's Low
¥4,715
Volume
5,947,000
Avg. Vol
2,296,556
52-wk High
¥5,170
52-wk Low
¥4,338

4502.T

Chart for 4502.T

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer... (more)

Overall

Beta: 0.63
Market Cap (Mil.): ¥3,678,193.00
Shares Outstanding (Mil.): 789.74
Dividend: 90.00
Yield (%): 3.86

Financials

  4502.T Industry Sector
P/E (TTM): -- 32.70 33.67
EPS (TTM): -- -- --
ROI: -- 18.12 17.39
ROE: -- 18.79 18.21
Search Stocks

CORRECTED-Nikkei falls after U.S. and German data sour mood; Fed eyed

(Corrects percentage decline in index and actual level in paragraph 5) * Strong retail sales lifts Seven & i, Aeon * Takeda soars after punitive damages slashed in Actos case * Fujifilm extends gains, but fund manager says its core business uncertain By Ayai Tomisawa TOKYO, Oct 28 - Japanese stocks fell Tuesday morning after Canon Inc tumbled on weak earnings and soft global data offset upbeat domestic retail figures as investors waited cautiously for the outcome o

27 Oct 2014

U.S. judge slashes $9 billion award vs Takeda, Lilly over diabetes drug

- A U.S. judge on Monday slashed a $9 billion punitive damages award to $36.8 million against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug, although she rejected their request for a new trial.

27 Oct 2014

U.S. judge slashes $9 billion award vs Takeda, Lilly over diabetes drug

- A U.S. judge on Monday slashed a $9 billion punitive damages award to $36.8 million against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug, although she rejected their request for a new trial.

27 Oct 2014

UPDATE 2-US judge slashes $9 bln award vs Takeda, Lilly over diabetes drug

Oct 27 - A U.S. judge on Monday slashed a $9 billion punitive damages award to $36.8 million against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug, although she rejected their request for a new trial.

27 Oct 2014

U.S. judge pares $9 bln award against Takeda, Eli Lilly over drug

NEW YORK, Oct 27 - A U.S. judge on Monday slashed a $9 billion punitive damage award against Takeda Pharmaceutical Co and Eli Lilly & Co over their Actos diabetes drug to $36.8 million, according to a court filing.

27 Oct 2014

BUZZ-Orexigen Therapeutics Inc: Diet drug launched

** Drugmaker's shares up 20 pct at $4.88, biggest intra-day percentage jump in more than two years

21 Oct 2014

Seattle Genetics and Takeda's cancer drug meets main trial goal

- Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

UPDATE 1-Seattle Genetics and Takeda's cancer drug meets main trial goal

Sept 29 - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

Seattle Genetics, Takeda's cancer drug meets main goal in trial

Sept 29 - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

29 Sep 2014

CORRECTED-UPDATE 1-Takeda, Lilly lose bid to overturn $9 bln award for hiding cancer risk

(Corrects number of decisions in Actos lawsuits from three to six in final paragraph)

30 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks